IP Library Granted Patent US 12,115,220
Granted Patent B2
US 12,115,220 · App. 17/309,186 · Granted Oct 15, 2024

Oral mucosal carrier and protectant

Inventor: Mark A. Latta (Omaha, NE)
Assignee: Inspired Material Solutions, LLC
A61K47/34A61K9/006A61K31/02A61K31/045A61K31/047A61K31/085A61K31/14A61K31/155A61K31/167A61K31/221A61K31/245A61K31/4164A61K31/4178A61K31/4425A61K31/7036A61K31/714A61K31/717A61K33/00A61K33/06A61K33/16A61K33/30A61K33/40A61K33/42A61K35/644A61K36/185A61K36/28A61K36/484A61K36/537A61K36/889A61K38/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,115,220
App. No.
17/309,186
Granted
Oct 15, 2024
Kind
B2
Abstract

An oral mucosal carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active agent.

Claims (20)

1. A dimethicone-based oral mucosal carrier comprising a first dimethicone material having a viscosity of between about 1,000 cP and 25,000 cP, and a second dimethicone material having a viscosity of between about 2.0 million and 3.0 million cP; and at least one active agent, wherein the ratio of the first dimethicone to the second dimethicone is between 100:1 and 1:10 wherein the concentration of the first dimethicone material is between 25% and 99% of the weight of the dimethicone-based oral mucosal carrier and the concentration of the second dimethicone material is between 1% and 50% of the weight of the dimethicone-based oral mucosal carrier.

2. The oral mucosal carrier of claim 1 wherein the active agent is selected from the group consisting of: a fluoride donor wherein the concentration of the fluoride donor is between 800 ppm and 1500 ppm, cetyl pyridinium chloride, benzalkonium chloride, and combinations thereof.

3. The oral mucosal carrier of claim 2 further comprising a calcium donor or a potassium donor.

4. The oral mucosal carrier of claim 1 further comprising a flavorant or a sweetener.

5. The oral mucosal carrier of claim 1 further comprising cetyl pyridinium chloride.

6. The oral mucosal carrier of claim 1 further comprising a bulking agent, a flowing agent, a preservative, or combinations thereof.

7. A method of formulating the oral mucosal carrier of claim 1 comprising placing a first dimethicone component into a mixing container and adding into it an amount of an active ingredient; mixing the first dimethicone component and the active ingredient at 3,000 RPM for a predetermined amount of time in a centrifugal mixer; and after mixing, adding to the now mixed material a first portion of a second dimethicone, wherein one fifth of the total concentration of the second dimethicone is added in separate increments and mixing the resulting material at 3,000 RPM for a predetermined period of time before adding another incremental portion of the second dimethicone, until all of the second dimethicone is added and admixed into the oral mucosal carrier wherein the concentration of the first dimethicone component is between 25% and 99% of the weight of the oral mucosal carrier and the concentration of the second dimethicone is between 1% and 50% of the weight of the oral mucosal carrier.

8. An oral mucosal carrier composition comprising: a dimethicone-based oral mucosal carrier comprising a first dimethicone material having a viscosity of between about 1,000 cP and 25,000 cP, and a second dimethicone material having a viscosity of between about 2.0 million and 3.0 million cP; and at least one active agent, wherein the ratio of the first dimethicone to the second dimethicone is between 100:1 and 1:10 wherein the concentration of the first dimethicone material is between 25% and 99% of the weight of the oral mucosal carrier composition and the concentration of the second dimethicone material is between 1% and 50% of the weight of the oral mucosal carrier composition.

9. The composition of claim 8 wherein the composition comprises two or more active agents.

10. The composition of claim 8 further comprising a bulking agent, wherein the bulking agent is selected from the group consisting of: an edible wax, a fat, an oil, mannitol, dicalcium phosphate, calcium sulfate, dry starch, cellulose, kaolin, anhydrous lactose, sorbitol, sucrose, and combinations thereof.

11. The composition of claim 10 wherein the bulking agent comprises between 0.01% and 15% of the total weight of the composition.

12. The composition of claim 8 wherein the active agent is a therapeutic agent selected from the group consisting of: sodium fluoride, difluorosilane, stannous fluoride, APF (acidulated phosphate fluoride), ACPF (amorphous calcium phosphate fluoride), ACP (amorphous calcium phosphate), sodium monofluorophosphate, benzalkonium chloride, potassium phosphate dibasic, calcium nitrate, cetylpyridinium chloride, phosphate donors, potassium donors, antibacterial, antifungal, antiviral, small molecules, antiemetic materials, biologic materials, self-replicating peptides, cannabinoids, terpenes, and combinations thereof.

13. The composition of claim 8 wherein the active agent is a hemp extract.

14. The composition of claim 8 wherein the active agent is a dry mouth treating agent selected from the group consisting of: pilocarpine, acetylcholine, electrolytes such as sodium, potassium, calcium, magnesium, chloride, phosphate, carbonates, and combinations thereof.

15. The composition of claim 8 wherein the active agent is a saliva enhancer selected from the group consisting of: essential oil extracts, spilanthes, xylitol, carboxymethylcellulose and variations of the same to enhance saliva flow.

16. The composition of claim 8 wherein the active agent is a halitosis treatment agent selected from the group consisting of: an antibacterial compound, a natural or synthetic oil, an odor destroying agent, and an odor masking agent.

17. The composition of claim 8 wherein the active agent is a canker sore treating agent selected from the group consisting of: alum powder (potassium aluminum sulfate), baking soda, probiotics, honey, coconut oils or other natural oil having antimicrobial properties, magnesium hydroxide, chamomile, echinacea, sage, deglycyrrhizinated licorice (DGL), zinc, vitamin B12, antimicrobial compounds, and combinations thereof.

18. The composition of claim 8 wherein the active agent is a dry socket treatment agent selected from the group consisting of: a pain relief agent, an antibacterial agent, and a tissue growth agent.

19. The composition of claim 18 wherein the active agent is selected from the group consisting of: NSAID, opioid, acetaminophen, chlorhexidine, metronidazole, guaiacol, eugenol, balsam of Peru, chlorobutanol, iodoform, butamben, polymyxin B sulfate, tyrothricin, neomycin sulfate, tetracaine hydrochloride, and combinations thereof.

20. The composition of claim 8 wherein the active agent is a peroxide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2024
From: INSPIRED MATERIAL SOLUTIONS, LLC
To: INSPIRED MATERIAL STRATEGIES, LLC
Reel/Frame 069477/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2021
From: LATTA, MARK A.
To: INSPIRED MATERIAL SOLUTIONS, LLC
Reel/Frame 056140/0016 →
Continuity (3)
Provisional Application 62755722 · Nov 5, 2018
Provisional Application 62846763 · May 13, 2019
Related Publication 20220023426A1 · Jan 27, 2022